Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B known ✓ | P35368 | 7/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazosin SCHEMBL41257 | 1.00 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL1172954 | 1.00 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29908896 | 1.00 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL11656542 | 0.99 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL9663302 | 0.99 | KDM4E (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL26524 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29376126 | 0.99 | ADRA1B (1.00) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL41258 | 0.97 | ADRA1B (0.96) | ADRA1BADRA1AKDM4EGLAGAA | |
| Prazosin SCHEMBL29157754 | 0.96 | ADRA1A (0.94) | ADRA1BADRA1AKDM4EGLAGAA | |
| SCHEMBL7797445 | 0.95 | ADRA1B (0.93) | ADRA1BADRA1AKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-7879802-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20090048175-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | SYNERGY PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040025-A9 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | ADRA1B 729/4885ADRA1A 813/4885ADRA1D 858/4885 |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | ADRA1B 729/4885ADRA1A 813/4885ADRA1D 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.